<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03322475</url>
  </required_header>
  <id_info>
    <org_study_id>Focus-PiQo4 Rejuvenation-17-02</org_study_id>
    <nct_id>NCT03322475</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of PiQo4 for Facial Skin Rejuvenation</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of PiQo4 for Facial Skin Rejuvenation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Focus Medical, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Focus Medical, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of at least 20 healthy subjects at a single site, with at least two facial sub-areas&#xD;
      with visible wrinkles with pigmentation and/or acne scars who wish to improve their skin&#xD;
      appearance will be enrolled into the study. subjects will receive 3 treatments and return to&#xD;
      follow-up visits at 1, 3, and 6 months following the last treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 12, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fitzpatrick Elastosis Score (FES) scale</measure>
    <time_frame>Baseline, 1 month follow up</time_frame>
    <description>Fine lines/wrinkles and elastosis improvement will be classified by the Fitzpatrick-Goldman Elastosis and Wrinkles scales: Class I, Class II or Class III.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Global Aesthetic Improvement (GAI) Scale</measure>
    <time_frame>Baseline, 1 month follow up</time_frame>
    <description>The global aesthetic improvement (GAI) scale will be used by the investigator to grade improvement in the following categories: 1) Fine lines/wrinkles; 2) texture 3) Pigmentation 4) Acne scars. Score 0-Worse, Score 1-No Change, Score 2- Somewhat improved, Score 3- Moderately improved, Score 4-Very Much Improved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fitzpatrick Elastosis Score (FES) scale</measure>
    <time_frame>Baseline, 3 month follow up</time_frame>
    <description>Skin improvement on the FES scale will be classified by the Fitzpatrick-Goldman Elastosis and Wrinkles scales at the 3 month-follow-up visits as compared to baseline.&#xD;
Classification: Class I, Class II or Class III.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Skin Rejuvenation</condition>
  <arm_group>
    <arm_group_label>Facial skin rejuvenation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Facial skin rejuvenation using PiQo4 laser system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PiQo4 laser system</intervention_name>
    <description>The PiQo4 laser system</description>
    <arm_group_label>Facial skin rejuvenation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following inclusion criteria to be entered into the study:&#xD;
&#xD;
          -  Healthy Female/Male.&#xD;
&#xD;
          -  Age= 18-70 (Adults).&#xD;
&#xD;
          -  Fitzpatrick skin phototype = I-V&#xD;
&#xD;
          -  Exhibiting at least two facial sub-areas with visible wrinkles with pigmentation&#xD;
             and/or acne scars.&#xD;
&#xD;
          -  Able to read, understand and provide written Informed Consent.&#xD;
&#xD;
          -  Able and willing to comply with the treatment/follow-up schedule and post treatment&#xD;
             care&#xD;
&#xD;
          -  Willingness to provide a brief medical history including disclosure of any prescribed&#xD;
             or over-the-counter medications taken within the past 6 months.&#xD;
&#xD;
          -  Willingness to allow Focus Medical (the study Sponsor) and Lumenis and the&#xD;
             investigators to use de-identified photographs of the treated area for presentation&#xD;
             and publication purposes.&#xD;
&#xD;
          -  Daily use of sunscreen for the duration of the study&#xD;
&#xD;
          -  Women of child-bearing potential are required to use a reliable method of birth&#xD;
             control (such as an intrauterine device, birth control pills, condom with spermicidal,&#xD;
             NuvaRing, partner with vasectomy, Implanon or other FDA-approved devices, or&#xD;
             abstinence) during the course of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any of the following will exclude the subject from the study:&#xD;
&#xD;
          -  Pregnant, intending to become pregnant during the course of study, less than 3 months&#xD;
             postpartum or less than 3 months after completion of breastfeeding&#xD;
&#xD;
          -  Prior skin laser, light or other energy device treatment in treated area within 6&#xD;
             months of initial treatment or during the course of the study.&#xD;
&#xD;
          -  Known hypersensitivity or contraindications to anesthetic agents including lidocaine&#xD;
             and its derivatives, and Toradol.&#xD;
&#xD;
          -  Having a history of diseases stimulated by heat, such as recurrent Herpes Simplex in&#xD;
             the treated area, unless treatment is conducted following a prophylactic regimen.&#xD;
&#xD;
          -  History of post inflammatory pigmentary disorders, particularly a tendency for hyper-&#xD;
             or hypo-pigmentation.&#xD;
&#xD;
          -  Having Melasma.&#xD;
&#xD;
          -  Having multiple dysplastic Nevi in are to be treated.&#xD;
&#xD;
          -  Having an excessive underlying vascular conditions (e.g. dense network of&#xD;
             capillaries).&#xD;
&#xD;
          -  History of keloid scarring or of abnormal wound healing.&#xD;
&#xD;
          -  Suffering from current or history of significant skin conditions in the treated area&#xD;
             or inflammatory skin conditions.&#xD;
&#xD;
          -  History of immunosuppression/immune deficiency disorders (including HIV infection or&#xD;
             AIDS) or currently using immunosuppressive medications.&#xD;
&#xD;
          -  Having a known anticoagulative or thromboembolic condition or taking anticoagulation&#xD;
             medications one week prior to and during the treatment course (to allow inclusion,&#xD;
             temporary cessation of use as per the subject's physician's discretion).&#xD;
&#xD;
          -  Having a neurological disorder (including Multiple Sclerosis, Parkinson's disease).&#xD;
&#xD;
          -  Having seizure disorder.&#xD;
&#xD;
          -  Having fibromyalgia.&#xD;
&#xD;
          -  Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning&#xD;
             during the study.&#xD;
&#xD;
          -  Participation in a study of another device or drug within three months prior to&#xD;
             enrolment or during the study.&#xD;
&#xD;
          -  Significant concurrent illness (e.g. uncontrolled diabetes) or any disease state that&#xD;
             in the opinion of the Investigator would interfere with the treatment or healing&#xD;
             process&#xD;
&#xD;
          -  As per the Investigator's discretion, any physical or mental condition which might&#xD;
             make it unsafe for the subject to participate in this study.&#xD;
&#xD;
          -  Subjects who are opposed to possible damage to the hair follicles with possible loss&#xD;
             of hair in the treatment area.&#xD;
&#xD;
          -  Received the following treatments in the area of the face to be treated during or&#xD;
             within the noted timeframes prior to the study treatment:&#xD;
&#xD;
               1. Dermabrasion or chemical peel treatment within 3 months.&#xD;
&#xD;
               2. Any devices and/or Botox treatment within 6 months.&#xD;
&#xD;
               3. Collagen/fat injections or other methods of augmentation with injected or&#xD;
                  implanted material in the treated area within 9 months.&#xD;
&#xD;
               4. Resurfacing procedure, face lift or eyelid surgery within a year.&#xD;
&#xD;
               5. Having a permanent implant in the facial skin area, such as an injected chemical&#xD;
                  substance.&#xD;
&#xD;
               6. Any other surgery in treated area within 9 months of initial treatment or during&#xD;
                  the course of the study&#xD;
&#xD;
               7. Use of retinoids, antioxidants or therapeutic skin nourishing supplements at&#xD;
                  medicinal concentration within 2 months and oral retinoids within 6 months of the&#xD;
                  study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Ross, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Clinic Carmel Valley</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edward Ross, MD</last_name>
    <phone>(858) 764-3023</phone>
    <email>Olafson.Tierney@scrippshealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tierney Olafson</last_name>
    <phone>(858) 764-3023</phone>
    <email>Olafson.Tierney@scrippshealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Scripps Clinical Research Services</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <last_update_submitted>March 6, 2019</last_update_submitted>
  <last_update_submitted_qc>March 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

